Workflow
BGI Genomics(300676)
icon
Search documents
★国家发展改革委召开科技型民营企业座谈会 支持民企在推动科技创新等方面发挥更加积极作用
Group 1 - The National Development and Reform Commission (NDRC) is focusing on gathering opinions for the "14th Five-Year Plan" with an emphasis on technological innovation and industry integration [1][2] - Private enterprises are seen as a crucial foundation for China's high-quality economic development, with strong innovation capabilities and potential [2] - The NDRC plans to incorporate suggestions from private enterprises into the "14th Five-Year Plan" to support their role in promoting technological innovation and building a modern industrial system [2] Group 2 - The meeting highlighted that the next 5 to 10 years are critical for breakthroughs in technology, leveraging China's institutional advantages and vast market potential [1] - Participating companies expressed the need for stronger support in funding, talent, energy, and data to enhance technological innovation and product iteration [1] - Companies committed to increasing R&D investment and strengthening independent innovation to contribute to national development strategies and high-quality economic growth [1]
华大基因(300676) - 关于控股股东部分股份质押的公告
2025-06-20 08:48
证券代码:300676 证券简称:华大基因 公告编号:2025-039 注:本次质押股份不涉及负担重大资产重组等业绩补偿义务。 (二)控股股东及其一致行动人股份累计质押情况 一、控股股东及其一致行动人部分股份质押的基本情况 | | 是否为控股 股东或第一 | 本次质押数 | 占其所持 | | 是否为限 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 占公司 | 售股(如 | 是否为 | 质押起 | 质押到期 | | 质押用 | | 股东名称 | 大股东及其 | 量(股) | 股份比例 | 总股本 | 是,注明 | 补充质 | 始日 | 日 | 质权人 | 途 | | | 一致行动人 | | | 比例 | 限售类 | 押 | | | | | | | | | | | 型) | | | | 中国邮政 | | | | | | | | | | | 至办理解 | 储蓄银行 | 自身生 | | 深圳华大 | | | | | | | | | | | | 基因科技 | 是 | | | | 否 | ...
华大基因(300676) - 关于控股股东部分股份质押的公告
2025-06-17 09:28
证券代码:300676 证券简称:华大基因 公告编号:2025-038 深圳华大基因股份有限公司 关于控股股东部分股份质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司(以下简称公司或上市公司)近日收到公司控股股东 深圳华大基因科技有限公司(以下简称华大控股)的通知,获悉华大控股将其持有的 部分公司股份办理了质押,相应的质押登记手续已通过中国证券登记结算有限责任 公司深圳分公司办理完毕。现将具体事项公告如下: 一、控股股东及其一致行动人部分股份质押的基本情况 | | 是否为控股 股东或第一 | 本次质押数 | | | 是否为限 | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 占其所持 | 占公司 | 售股(如 | 是否为 | 质押起 | 质押到期 | | 质押用 | | 股东名称 | 大股东及其 | 量(股) | 股份比例 | 总股本 | 是,注明 | 补充质 | 始日 | 日 | 质权人 | 途 | ...
华大基因(300676) - 关于完成注册地址变更并换发营业执照的公告
2025-06-12 10:44
证券代码:300676 证券简称:华大基因 公告编号:2025-037 近日,公司已完成注册地址的工商变更登记手续以及《公司章程》的工商备 案手续,公司注册地址由"深圳市盐田区洪安三街21号华大综合园7栋7层-14层" 变更为"深圳市盐田区梅沙街道滨海社区云华路9号华大时空中心B栋8南1-1", 并取得了深圳市市场监督管理局换发的《营业执照》。同时,根据工商登记机关 最终核准的注册地址对《公司章程》进行相应条款的修订。 除上述注册地址变更的修订条款外,《公司章程》其他条款内容不变。 三、备查文件 1、《深圳华大基因股份有限公司营业执照》; 2、深圳市市场监督管理局出具的变更登记和换发证照通知书。 深圳华大基因股份有限公司 关于完成注册地址变更并换发营业执照的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 一、公司注册地址变更的情况说明 深圳华大基因股份有限公司(以下简称"公司")分别于2025年4月24日、2025 年5月20日召开第四届董事会第五次会议、2024年年度股东会,审议通过《关于变 更注册地址并修订<公司章程>的议案》。具体内容详见公司于20 ...
华大基因重磅发布!
Zhong Guo Ji Jin Bao· 2025-06-11 03:04
Core Viewpoint - BGI Genomics has officially established a strategic partnership with the Shenzhen Data Exchange, launching its first comprehensive tumor database, marking a significant step towards transforming into a data-driven intelligent medical ecosystem [2][9]. Group 1: Strategic Cooperation - The partnership aims to deepen collaboration in key areas such as data product innovation, industry data standard construction, data compliance and security, financialization of data assets, and data space development [2]. - BGI Genomics is transitioning from a traditional genetic testing service provider to a data-driven intelligent medical ecosystem, leveraging its proprietary platform and technological advantages to build a comprehensive database reflecting the genetic characteristics of the Chinese population [9][11]. - The cooperation is seen as a critical move to construct an autonomous data ecosystem and implement the national strategy of "data elements × healthcare" [9]. Group 2: Industry Context - The global precision medicine market is experiencing rapid growth, and China's data element market reform is making significant breakthroughs, with Shenzhen leading the way by establishing a data exchange and regulatory framework for compliant data circulation [4][5]. - The collaboration is positioned as a key starting point for the value development of genetic data, aiming to explore innovative paths for compliant development and application of genetic data [11]. - The initiative addresses critical industry challenges such as data security, privacy protection, and complex regulatory compliance, providing a systematic framework to enhance overall governance in the sector [13]. Group 3: Product Launch - BGI Genomics has launched a gene data product, the comprehensive tumor database, which integrates authoritative global genetic variation and treatment data while focusing on clinical guidelines and practice data unique to China [13]. - This product aims to provide high-value data services for precision medicine research and alleviate challenges associated with reliance on international databases [13].
华大基因(300676) - 关于2022年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期归属结果暨股份上市的公告
2025-06-09 10:48
重要内容提示: 1、本次归属股票上市流通日:2025 年 6 月 11 日(星期三); 2、本次归属人数:421 人(首次授予与预留授予归属人数存在部分重合), 其中,首次授予部分第二个归属期归属人数为 417 人;预留授予部分第一个归属 期归属人数为 18 人; 深圳华大基因股份有限公司 关于 2022 年限制性股票激励计划首次授予部分第二个归属期及 预留授予部分第一个归属期归属结果暨股份上市的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记 载、误导性陈述或重大遗漏。 证券代码:300676 证券简称:华大基因 公告编号:2025-036 一、本激励计划实施情况概要 (一)本激励计划简述及授予情况 1 3、本次归属股票数量:249.55 万股,占公司目前总股本的 0.60%;其中,首 次授予部分第二个归属期归属股票数量 179.55 万股,预留授予部分第一个归属期 归属股票数量 70 万股; 4、本次归属的限制性股票授予价格(调整后):27.73 元/股; 公司于 2022 年 11 月 18 日、2022 年 12 月 6 日分别召开第三届董事会第十三 次会议、2022 年第五 ...
4.14亿主力资金净流入 辅助生殖概念涨3.33%
Group 1 - The assisted reproductive concept sector increased by 3.33%, ranking 10th among concept sectors, with 68 stocks rising, including Haichen Pharmaceutical which hit a 20% limit up, and others like Zhongsheng Pharmaceutical, Meinuo Pharmaceutical, and Shuanglu Pharmaceutical also reaching their limit up [1][2] - Notable gainers in the assisted reproductive sector included Xinghao Pharmaceutical, Shengnuo Biological, and Saiseng Pharmaceutical, which rose by 27.29%, 17.58%, and 6.08% respectively [1][6] - The sector saw a net inflow of 414 million yuan from main funds, with 31 stocks receiving net inflows, and 6 stocks exceeding 30 million yuan in net inflow, led by Zhongsheng Pharmaceutical with a net inflow of 247 million yuan [2][3] Group 2 - The top three stocks by net inflow ratio in the assisted reproductive sector were Zhongsheng Pharmaceutical at 55.08%, Shuanglu Pharmaceutical at 20.11%, and Meinuo Pharmaceutical at 17.33% [3][4] - The trading volume and turnover rates for leading stocks in the sector were significant, with Zhongsheng Pharmaceutical showing a daily increase of 9.99% and a turnover rate of 3.84% [3][4] - Other stocks with notable performance included Fuxing Pharmaceutical with a 3.60% increase and a turnover rate of 2.17%, and Meinuo Pharmaceutical with a 9.97% increase and a turnover rate of 7.37% [3][4]
稀土永磁板块异动走高,A500指数ETF(159351)成交额暂居同标的产品第一,机构:预计稀土价格有望继续温和上涨
Group 1 - The core viewpoint of the news highlights the recent surge in the rare earth permanent magnet sector, driven by export control measures and market dynamics [1][2] - The A500 Index ETF (159351) has shown a positive performance, with a 0.62% increase and a trading volume exceeding 2 billion yuan, indicating strong investor interest [1][2] - The rare earth industry is experiencing a supply tightening and price stabilization, with expectations for moderate price increases benefiting equity sector profitability [2] Group 2 - The A500 Index ETF closely tracks the CSI A500 Index, which includes 500 representative stocks across various industries, balancing large-cap stocks with core industry leaders [2] - The A-share market is seen as having the potential for a bull market, driven by increasing household asset allocation towards equities and improvements in corporate governance and shareholder returns [3] - The overall profitability of Chinese enterprises is expected to rise, with a historical supply clearing cycle anticipated, indicating a shift towards higher value sectors [3]
华大基因收盘上涨3.83%,最新市净率2.39,总市值217.31亿元
Sou Hu Cai Jing· 2025-05-29 10:40
Group 1 - The core business of the company includes gene testing, mass spectrometry testing, bioinformatics analysis, and medical AI models, providing comprehensive solutions for research services, precision medical testing, and health management [2] - The company has received multiple awards, including the "2023 Chinese Preventive Medicine Association Science and Technology Award" and recognition in the ESG field for its management practices [2] - The latest financial report shows a revenue of 672 million yuan for Q1 2025, a year-on-year decrease of 18.18%, and a net loss of approximately 52.7 million yuan, with a gross profit margin of 43.55% [3] Group 2 - As of May 29, the company's stock closed at 52.26 yuan, up 3.83%, with a latest price-to-book ratio of 2.39 and a total market capitalization of 21.731 billion yuan [1] - On May 29, the company experienced a net inflow of main funds amounting to 13.51 million yuan, with a total inflow of 57.99 million yuan over the past five days [1] - The company's price-to-earnings ratio (TTM) is -22.45, indicating a negative earnings performance compared to the industry average of 49.64 [3]
华大基因(300676) - 关于第二期员工持股计划首次授予部分第二个锁定期届满的提示性公告
2025-05-29 09:26
证券代码:300676 证券简称:华大基因 公告编号:2025-035 深圳华大基因股份有限公司 关于第二期员工持股计划首次授予部分第二个锁定期届满的 提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假 记载、误导性陈述或重大遗漏。 深圳华大基因股份有限公司(以下简称公司)第二期员工持股计划(以下简 称本持股计划)首次授予部分第二个锁定期将于 2025 年 6 月 1 日届满,根据《关 于上市公司实施员工持股计划试点的指导意见》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等法律法规及本持股计划的相关 规定,现将本持股计划首次授予部分第二个锁定期届满的相关情况公告如下: 一、本持股计划的实施进展和锁定期届满的情况说明 (一)本持股计划的实施进展 1、本持股计划的审议情况 公司于 2022 年 11 月 18 日召开第三届董事会第十三次会议和第三届监事会 第十四次会议,于 2022 年 12 月 6 日召开 2022 年第五次临时股东大会,审议通 过了《关于<深圳华大基因股份有限公司第二期员工持股计划(草案)>及其摘要 的议案》等相关议案,同意公司实施第 ...